MHC class I epitope specific protection and targeting of B16-OVA melanoma.

<p>(A) Vaccination with TMEV-wt or TMEV-L/OVA virus did not delay tumor outgrowth using the parental B16 tumor model. (B), Tumor outgrowth in mice challenged with B16-OVA tumor and vaccinated with TMEV-wt (top) or with TMEV-L/OVA (bottom). Tumor sizes were significantly different in these treatment groups on days 10 through 19 (* designates p<0.05). (C) G418 resistance and growth of tumor cells recovered from mice vaccinated with TMEV-wt or with TMEV-L/OVA (left). Quantitation of cresyl violet stained tumor cells recovered from vaccinated mice. Data expressed as the percent of well area containing stained tumor cells from TMEV-wt and TMEV-L/OVA vaccine treated mice (middle) (p<0.05). RNA isolated from recovered tumors was analyzed by qRT-PCR for the presence of ovalbumin specific transcripts (p = 0.009).